HAL (France)open access
Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension
Ustekinumab, Ulcerative colitis, Symptomatic remission, 0
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 665317
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.